10-Q: Regeneron Reports Q1 2025 Results: EYLEA HD Growth Partially Offsets EYLEA Decline, Dupixent Continues Strong Performance

Regeneron's Q1 2025 results show a slight revenue decrease year-over-year, with EYLEA HD growth partially offsetting EYLEA decline and Dupixent continuing its strong growth trajectory.

Summary

• Regeneron Pharmaceuticals reported its Q1 2025 financial results, with total revenues of $3.0287 billion, a slight decrease from $3.145 billion in Q1 2024.
• Net income increased to $808.7 million, or $7.27 per diluted share, compared to $722.0 million, or $6.27 per diluted share, in the prior year.
• EYLEA HD U.S. net product sales increased to $306.8 million from $200.0 million, while EYLEA U.S. net product sales decreased to $736.0 million from $1.2016 billion.
• Global Libtayo net product sales increased to $285.1 million from $263.9 million.
• Collaboration revenue from Sanofi increased to $1.1832 billion from $909.8 million, driven by Dupixent.
• Collaboration revenue from Bayer decreased slightly to $343.9 million from $356.0 million.
• Research and development expenses increased to $1.3274 billion from $1.2484 billion.
• The company repurchased 1.5 million shares of its common stock for $1.0524 billion.
• Regeneron paid a dividend of $0.88 per share in March 2025 and declared another dividend of the same amount for June 2025.
• The company expects capital expenditures of $850 million to $950 million for the full year of 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While EYLEA sales are declining, EYLEA HD is growing, and Dupixent continues to perform well. The company is also returning capital to shareholders. However, there are some regulatory and competitive headwinds.

Positives

• EYLEA HD is showing strong growth, partially offsetting the decline in EYLEA sales.
• Dupixent continues to perform well, driving significant collaboration revenue.
• The company is returning capital to shareholders through share repurchases and dividends.
• Libtayo global sales are increasing.
• Net income and earnings per share increased year-over-year.

Negatives

• EYLEA sales are declining significantly due to competition and the transition to EYLEA HD.
• Total revenues decreased slightly year-over-year.
• The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe, delaying its potential approval.
• A pre-planned interim analysis of two Phase 2/3 studies evaluating the combination of fianlimab and cemiplimab in first-line advanced NSCLC will continue unchanged until additional data are available, with the next analyses expected in the first quarter of 2026.

Risks

• Increased competition from biosimilars and other anti-VEGF products could further erode EYLEA sales.
• Delays in regulatory approvals for product candidates or new indications could impact future growth.
• Manufacturing or supply chain disruptions could affect the company's ability to meet demand.
• Changes in reimbursement policies or pricing pressures could impact profitability.
• The outcome of ongoing legal proceedings and government investigations is uncertain.
• The company's reliance on collaborations with Sanofi and Bayer poses risks if these collaborations are terminated or if the collaborators fail to perform their obligations.

Future Outlook

The company expects to incur capital expenditures of $850 million to $950 million for the full year of 2025, including in connection with the continued expansion of its facilities in Tarrytown, New York.

Industry Context

The report highlights the increasing competition in the ophthalmology market, particularly for VEGF inhibitors, with the entry of biosimilars and other novel therapies. The strong performance of Dupixent underscores the growing demand for biologics in immunology and inflammation. The company's strategic collaborations with Sanofi and Bayer remain crucial for driving revenue and expanding market reach.

Comparison to Industry Standards

• Regeneron's performance is being impacted by biosimilar competition to EYLEA, a trend affecting other companies in the biologics space, such as Amgen with Neupogen and Neulasta.
• The growth of Dupixent is comparable to the success of other biologics in immunology, such as AbbVie's Humira (prior to biosimilar entry) and Johnson & Johnson's Stelara.
• The company's R&D spending is in line with other large-cap biotechnology companies focused on developing innovative therapies, such as Gilead Sciences and Vertex Pharmaceuticals.
• The company's share repurchase and dividend programs are consistent with capital allocation strategies of mature biotechnology companies with strong cash flow generation, such as Amgen and Biogen.

Legal Proceedings

• The company is involved in various legal proceedings, including patent litigation related to EYLEA and antitrust litigation related to Praluent.
• The company is also subject to government investigations related to its support of 501(c)(3) organizations and remuneration paid to physicians.

Stakeholder Impact

• Shareholders will benefit from the company's share repurchase and dividend programs.
• Patients will benefit from the continued development and commercialization of innovative therapies.
• Employees will be impacted by the company's expansion and growth.
• The company's collaborations with Sanofi and Bayer will impact the development and commercialization of certain products.

Next Steps

• FDA decision on sBLA for RVO (target action date of August 19, 2025).
• FDA decision on sBLA for every 4-week dosing regimen (target action date of August 19, 2025).
• European Commission (EC) decision on regulatory submission for CSU in adults and adolescents (second half 2025).
• FDA decision on sBLA (target action date of June 20, 2025) and EC decision on regulatory submission (first half 2026) for bullous pemphigoid.
• Report results from Phase 3 AERIFY-1 and AERIFY-2 trials in COPD (mid-2025).
• MHLW decision on regulatory submission for NSCLC, monotherapy and chemotherapy combination (second half 2025).
• FDA decision on sBLA and EC decision on regulatory submission for adjuvant CSCC.
• Report results from Phase 3 study versus pembrolizumab in first-line metastatic melanoma (second half 2025).
• Initiate Phase 2 study (in combination with Libtayo) in first-line metastatic head and neck squamous cell carcinoma (2025).
• Report data from Phase 2/3 studies in first-line advanced NSCLC (first quarter 2026).
• Report additional data from study in platinum-resistant ovarian cancer (second half 2025).
• Report additional data from study in prostate cancer at American Association for Cancer Research (AACR) Annual Meeting.
• Report additional data from study in solid tumors (second half 2025).
• Report results from Phase 3 cemdisiran combination study in myasthenia gravis (second half 2025).
• FDA decision on BLA for relapsed/refractory FL (target action date of July 30, 2025).
• FDA decision on BLA for relapsed/refractory multiple myeloma (target action date of July 10, 2025).
• Initiate Phase 3 program (2025) for REGN9933 Antibody to Factor XI Thrombosis.
• Initiate Phase 3 program (2025) for REGN7508 Antibody to Factor XI Thrombosis.
• Report results from Phase 3 study in FOP (second half 2025).
• Report results from Phase 2 study in obesity (second half 2025).
• Report additional data from Phase 1/2 study for DB-OTO AAV-based gene therapy (mid-2025).
• Initiate Phase 3 program (2025) for REGN9933 Antibody to Factor XI Thrombosis.
• Initiate Phase 3 program (2025) for REGN7508 Antibody to Factor XI Thrombosis.

Key Dates

Keywords

Regeneron, EYLEA HD, EYLEA, Dupixent, Libtayo, Collaboration Revenue, Net Product Sales, Financial Results, Q1 2025, Biosimilars